Table 1.
Rab27A | Rab27B | |
---|---|---|
Promote cell growth (in vitro) | • Melanoma cells (WM1385, WM1960) [34] | • Breast cancer cells (MCF-7, T47D, ZR75.1) [35] |
Promote tumor growth (in vivo) | • Melanoma cells (SK-Mel-28, B16-F10) [26] • Breast cancer cells (4T1) [25] |
• Breast cancer cells (MCF-7) [35] |
Promote cell invasion (in vitro) | • Bladder cancer cells (T24, FL3) [27] | • Bladder cancer cells (T24, FL3) [27] • Breast cancer cells (MCF-7, T47D) [35] |
Promote tumor metastasis (in vivo) | • Melanoma cells (SK-Mel-28, B16-F10) [26] • Breast cancer cells (4T1) [35] |
• Breast cancer cells (MCF-7) [35] |
Increase chemoresistance (in vitro) | –– | • Breast cancer cells (MCF-7) [37] |
Increase exosome secretion (in vitro) | • Bladder cancer cells (T24, FL3) [27] • Cervical cancer cells (HeLa) [23] • Breast cancer cells (MDA-MB-231, 4T1) [24, 25] • Melanoma cells (SK-Mel-28, B16-F10) [26] • Lung adenocarcinoma cells (A529) [28] |
• Bladder cancer cells (T24, FL3) [27] • Cervical cancer cells (HeLa) [23] • Increase V-ATPase in exosome secretion of breast cancer cells (MCF-7) [49] • Increase HSP90α in exosome secretion of breast cancer cells (MCF-7) [35] |